FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367296087> ?p ?o ?g. }

• W4367296087 abstract "<h3>Objective:</h3> We sought to determine whether Anti-factor-Xa (AFXa) values are associated with outcomes in cerebral venous thrombosis (CVT). <h3>Background:</h3> Intravenous unfractionated heparin (UFH) is a cornerstone of anticoagulant therapy for patients with CVT, but frequent monitoring is needed because of dose-response variability. The AFXa assay is used to monitor UFH treatment. <h3>Design/Methods:</h3> This pilot study included adults (≥18y) admitted to a comprehensive stroke center from 2018 through 2020 who were initially treated for CVT with low-intensity UFH drip and had at least one AFXa assay. AFXa therapeutic values were defined as 0.25 – 0.5 IU/mL. We examined percent of patients who became therapeutic within 24h of arrival, and time (hours, h) to reach therapeutic range. Outcomes included hospital LOS, bleeding event, and discharge disposition. Continuous data are presented as median (interquartile range). <h3>Results:</h3> There were 51 CVT patients included. The time to start UFH was 2h (1–6) from arrival and the time to the first AFXa assay was 8h (4–11) from arrival. AFXa were drawn 4 (2–8) times per patient. AFXa assays were performed within 24h for 45 (88%) patients and 30(67%) patients were in the therapeutic range. There was no association between study outcomes and AFXa being therapeutic or not: bleeding events were 17.2% and 13.3%, respectively (p=1.0), discharge to home was 77% vs. 80% (p=1.0), and hospital LOS was 5 days for each group (p=0.95). There was also no association between study outcomes and the time (h) to reach therapeutic range: discharge home vs. other location (11h vs. 14h, p=0.49), development of a bleed vs. no bleed (9h vs. 12h, p=0.44), and no correlation with hospital LOS (p=0.55). <h3>Conclusions:</h3> The time to achieve therapeutic AFXa was not associated with outcomes, although most patients were within the target AFXa range within 24h of arrival and had favorable outcomes. <b>Disclosure:</b> Dr. Pirahanchi has nothing to disclose. Ms. Salottolo has nothing to disclose. Dr. Burrell has nothing to disclose. Dr. Tang has nothing to disclose. Dr. DiSalvo has nothing to disclose. David Bar-Or has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Ampio Pharmaceuticals. David Bar-Or has stock in Ampio Pharmaceuticals. Dr. Bartt has nothing to disclose." @default.
• W4367296087 created "2023-04-29" @default.
• W4367296087 creator A5018380510 @default.
• W4367296087 creator A5031497734 @default.
• W4367296087 creator A5042906130 @default.
• W4367296087 creator A5048283695 @default.
• W4367296087 creator A5058977361 @default.
• W4367296087 creator A5077883700 @default.
• W4367296087 creator A5089350102 @default.
• W4367296087 date "2023-04-25" @default.
• W4367296087 modified "2023-10-18" @default.
• W4367296087 title "No Association Between Outcomes And Anti-Factor Xa Levels For Heparin Monitoring In Patients With Cerebral Venous Thrombosis (P14-5.012)" @default.
• W4367296087 doi "https://doi.org/10.1212/wnl.0000000000203224" @default.
• W4367296087 hasPublicationYear "2023" @default.
• W4367296087 type Work @default.
• W4367296087 citedByCount "0" @default.
• W4367296087 crossrefType "proceedings-article" @default.
• W4367296087 hasAuthorship W4367296087A5018380510 @default.
• W4367296087 hasAuthorship W4367296087A5031497734 @default.
• W4367296087 hasAuthorship W4367296087A5042906130 @default.
• W4367296087 hasAuthorship W4367296087A5048283695 @default.
• W4367296087 hasAuthorship W4367296087A5058977361 @default.
• W4367296087 hasAuthorship W4367296087A5077883700 @default.
• W4367296087 hasAuthorship W4367296087A5089350102 @default.
• W4367296087 hasConcept C119060515 @default.
• W4367296087 hasConcept C126322002 @default.
• W4367296087 hasConcept C127413603 @default.
• W4367296087 hasConcept C19831878 @default.
• W4367296087 hasConcept C2777557582 @default.
• W4367296087 hasConcept C2778205648 @default.
• W4367296087 hasConcept C2778959117 @default.
• W4367296087 hasConcept C2780011451 @default.
• W4367296087 hasConcept C2780035454 @default.
• W4367296087 hasConcept C2780645631 @default.
• W4367296087 hasConcept C2780868729 @default.
• W4367296087 hasConcept C2991741193 @default.
• W4367296087 hasConcept C42219234 @default.
• W4367296087 hasConcept C71924100 @default.
• W4367296087 hasConcept C78519656 @default.
• W4367296087 hasConcept C98274493 @default.
• W4367296087 hasConceptScore W4367296087C119060515 @default.
• W4367296087 hasConceptScore W4367296087C126322002 @default.
• W4367296087 hasConceptScore W4367296087C127413603 @default.
• W4367296087 hasConceptScore W4367296087C19831878 @default.
• W4367296087 hasConceptScore W4367296087C2777557582 @default.
• W4367296087 hasConceptScore W4367296087C2778205648 @default.
• W4367296087 hasConceptScore W4367296087C2778959117 @default.
• W4367296087 hasConceptScore W4367296087C2780011451 @default.
• W4367296087 hasConceptScore W4367296087C2780035454 @default.
• W4367296087 hasConceptScore W4367296087C2780645631 @default.
• W4367296087 hasConceptScore W4367296087C2780868729 @default.
• W4367296087 hasConceptScore W4367296087C2991741193 @default.
• W4367296087 hasConceptScore W4367296087C42219234 @default.
• W4367296087 hasConceptScore W4367296087C71924100 @default.
• W4367296087 hasConceptScore W4367296087C78519656 @default.
• W4367296087 hasConceptScore W4367296087C98274493 @default.
• W4367296087 hasLocation W43672960871 @default.
• W4367296087 hasOpenAccess W4367296087 @default.
• W4367296087 hasPrimaryLocation W43672960871 @default.
• W4367296087 hasRelatedWork W144325104 @default.
• W4367296087 hasRelatedWork W2164436673 @default.
• W4367296087 hasRelatedWork W2266482471 @default.
• W4367296087 hasRelatedWork W2329820324 @default.
• W4367296087 hasRelatedWork W2348510513 @default.
• W4367296087 hasRelatedWork W2414818497 @default.
• W4367296087 hasRelatedWork W2418047912 @default.
• W4367296087 hasRelatedWork W2440780352 @default.
• W4367296087 hasRelatedWork W3026185187 @default.
• W4367296087 hasRelatedWork W4230146141 @default.
• W4367296087 isParatext "false" @default.
• W4367296087 isRetracted "false" @default.
• W4367296087 workType "article" @default.